Please login to the form below

Not currently logged in

AZ's Lisa Anson elected president of ABPI

She takes up the lead role from April 2017

AZ Lisa AnsonThe Association of the British Pharmaceutical Industry has elected Lisa Anson to serve as its president from the end of April next year.

Anson joined the ABPI board in 2012 and has since overseen a number of schemes for the association, including the implementation of the Pharmaceutical Pricing Regulation Scheme.

Currently serving as president of AstraZeneca UK and Ireland, Anson has held several senior management positions at the firm, including vice president of emerging brands.

She brings further pharmaceutical management experience from California-based Salick Health Care, where she was vice president of strategy, and management consultancy expertise from KPMG.

Mike Thompson, the ABPI's chief executive said: “The unanimous decision by the ABPI board to elect Lisa Anson as president shows the esteem in which she is held.

“As a high profile president of AstraZeneca UK and Ireland her knowledge and experience will be valuable as we head into what is arguably the UK pharmaceutical industry's most challenging era to date.

“Lisa will play a leading role as we negotiate the future of our industry outside the European Union and as we work with government to build an industrial strategy with life-sciences at its heart.

“Speaking on behalf of the board and all staff at the ABPI, we very much look forward to working with Lisa.”

14th December 2016

From: Healthcare



Featured jobs

Subscribe to our email news alerts


Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...